"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"

Inclusion Criteria: * Diagnosis of clinically possible or probable DLB using established criteria * Age 50-90 inclusive * Epworth Sleepiness Scale score of 8 or greater * MMSE score between 10 and 26 inclusive * No active medical disorder that could preclude participation in a drug treatment trial over a 12 week protocol * Stable medication regimen over previous four weeks * Absence of psychotropic medications at doses viewed by the clinician to be significantly impacting the patient's alertness during wakefulness * Absence of clinically significant primary sleep-related breathing disorder causing sleepiness as demonstrated by polysomnography (PSG) \[ie, no significant upper airway resistance syndrome (UARS), obstructive sleep apnea (OSA), nor central sleep apnea (CSA) as reflected by a combined respiratory disturbance index (RDI) \<15\] OR adequate documentation of efficacy of treatment for UARS, OSA, and CSA * Caregiver that is with the patient at least 4 hours/day for at least 5 days per week * Patient and caregiver willing and able to participate in all study-related procedures * Patient is capable of giving informed consent, or if appropriate, has caregiver capable of giving consent on the subject's behalf. Exclusion Criteria: * Does not fulfill criteria for clinically possible or probable DLB * Age \<50 or \>90 * Women with intact uterus and not post-menopausal unless pregnancy test performed at screening is negative * Epworth Sleepiness Scale score less than 8 * MMSE score \<10 or \>26 * Active medical disorder that could preclude participation in a drug treatment trial over a 52 week protocol, such as: * Hypertension with BP readings exceeding 150 mm Hg systolic and 90 mm Hg diastolic * Hypersensitivity to modafinil, armodafinil, or any other conventional stimulants * Myocardial infarction or cerebral infarct over preceding year, stable or unstable angina, known symptomatic coronary artery disease * History of left ventricular hypertrophy or mitral valve prolapse * History of chronic or paroxysmal atrial fibrillation, chronic or paroxysmal atrial flutter, ventricular fibrillation, or ventricular tachycardia * History of cancer over preceding 1 year (excluding squamous or basal cell carcinoma of the skin) * History of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS) * Pulmonary disease requiring oral or inhalatory medications * Any other medical disorder considered by the study physicians as inappropriate for any wake-promoting medication * Medication regimen has not been stable over preceding four weeks * Concurrent use of lamotrigine or oxcarbazepine * Presence of over-the-counter and prescription psychotropic medications at doses viewed by the clinician to be significantly impacting the patient's alertness during wakefulness, such as: * Clonazepam \> 1 mg/night * Seroquel \> 100 mg/night * Zyprexa \> 10 mg/night * Presence of another clinically-significant primary sleep disorder (eg, UARS, OSA, CSA) that is not being treated * Clinically significant abnormalities on screening ECG or laboratory tests * Patient or caregiver unwilling or unable to participate in all study-related procedures * Caregiver is not with patient at least 4 hours/day for at least 5 days/week * Patient or caregiver unwilling or unable to provide informed consent * CT or MRI evidence of a clinically significant structural lesion that could account for the participants dementia